Kintara Therapeutics Inc NASDAQ KTRA

Kintara Therapeutics Inc. is a small company headquartered in San Diego, California. The company employs 9 people and reports revenue of over $10,000. Kintara Therapeutics focuses on the development of novel cancer therapies for patients with unmet medical needs. They are working on two primary drug candidates: VAL-083 and REM-001. VAL-083 is a small molecule DNA-targeting agent that has shown promise in pre-clinical and clinical trials for treating glioblastoma multiforme, ovarian cancer, and pediatric CNS tumors. REM-001 is a second-generation photosensitizer drug being investigated for cutaneous metastatic breast cancer, recurrent basal cell carcinoma nevus syndrome, and hemodialysis arteriovenous (AV) access. Kintara Therapeutics collaborates with academic and clinical research institutions worldwide to advance their drug development programs. Kintara Therapeutics can be contacted through their website, kintara.com.